| Date: | Wed, 13 May 2009 10:47:44 -0500 |
|---|
| Reply-To: | Mary <mlhoward@AVALON.NET> |
|---|
| Sender: | "SAS(r) Discussion" <SAS-L@LISTSERV.UGA.EDU> |
|---|
| From: | Mary <mlhoward@AVALON.NET> |
|---|
| Subject: | Re: Copyright (c) 2008 Paul OldenKamp |
|---|
|
| Content-Type: | text/plain; format=flowed; charset="Windows-1252";
reply-type=original |
|---|
There's an interesting article on gene copywriting in the New York Times:
http://www.nytimes.com/2009/05/13/health/13patent.html?ref=us
A woman with breast cancer wants to be screened for ovarian cancer, but
Myriad Genetics holds the patent to the gene and claims it has exclusive
rights to do the screening, but the woman's health insurance won't pay for
the screening because it thinks Myriad Genetics fees are too high.
-Mary
----- Original Message -----
From: "Kevin Viel" <citam.sasl@GMAIL.COM>
To: <SAS-L@LISTSERV.UGA.EDU>
Sent: Monday, May 04, 2009 8:14 AM
Subject: Re: Copyright (c) 2008 Paul OldenKamp
>
> No clue, but if you think that is curious, you should see what the patent
> office is handling with regards to DNA data. I guess "trivial" is a
> matter of perspective?
>
> You might actually have to pay to genotype certain loci, although in the
> one case with which I am familiar, academic/research use was exempted....
>
> -Kevin
| 
